CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals

Marta del Campo*, Carlos Quesada, Lisa Vermunt, Carel F.W. Peeters, Yanaika S. Hok-A-Hin, Calvin Trieu, Anouk den Braber, Inge M.W. Verberk, Pieter J. Visser, Betty M. Tijms, Wiesje M. van der Flier, Charlotte E. Teunissen

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademic

Abstract

This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established.

Original languageEnglish
Article number82
JournalMolecular Neurodegeneration
Volume19
DOIs
Publication statusPublished - 11 Nov 2024

Fingerprint

Dive into the research topics of 'CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals'. Together they form a unique fingerprint.

Cite this